Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
ARCT compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name
ARCT
Arcturus Therapeutics Holdings Inc.
Change
Mkt cap
Revenue
Revenue
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
vs
Compare
ARCT
Arcturus Therapeutics Holdings Inc.
vs
LLY
ELI Lilly & Co
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Earnings history
Desk
News
Calendar
Saved
Search
Earnings history
last 4 reports each · paired by recency
Method
›
ARCT
1 of 4
at or beyond implied
Report
implied
realized
× implied
Q2 FY26
±21.8%
▲
+21.88%
×1.00
May 8 '26
±15.5%
▲
+3.60%
×0.23
Q1 FY26
±18.3%
▼
−4.17%
×0.23
Q3 FY25
±10.9%
▼
−1.25%
×0.12
LLY
3 of 4
at or beyond implied
Report
implied
realized
× implied
Q3 FY26
±5.1%
▲
+6.63%
×1.29
Q2 FY26
±6.2%
▲
+4.86%
×0.79
= implied
ARCT realized, solid
LLY realized, hatched
One scale, both sides: full bar = 22%
× = |realized| ÷ implied
Source: market data
Q1 FY26
±5.3%
▲
+9.80%
×1.85
Feb 4 '26
±6.1%
▲
+10.33%
×1.69
ARCT
Arcturus Therapeutics Holdings Inc.
Change
9.37
· pre 9.37
· delayed
Mkt cap
$269.8M
Revenue
$18M
Q3 FY26
Revenue
$82M
FY25
LLY
ELI Lilly & Co
Change
1,371.32
· pre 1,350.47
· delayed
Pre-market
Nov 6 '26
delayed
Mkt cap
$1.2T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
vs
Compare
Pre-market
Nov 6 '26
delayed
ARCT
Arcturus Therapeutics Holdings Inc.
vs
LLY
ELI Lilly & Co
9.37
pre 9.37
delayed
Price
1,371.32
pre 1,350.47
delayed
$269.8M
Mkt cap
$1.2T
Q3 FY26
$18M
Revenue
$24.4B
Q3 FY26
FY25
$82M
Revenue
$65.2B
FY25
Change
Change
ARCT
9.37
vs
LLY
1,371.32
Pre-market
Nov 6 '26
delayed